KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash & Equivalents (2016 - 2025)

TherapeuticsMD's Cash & Equivalents history spans 16 years, with the latest figure at $7.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 47.91% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $7.5 million, up 47.91%, while the annual FY2025 figure was $7.5 million, 47.91% up from the prior year.
  • Cash & Equivalents reached $7.5 million in Q4 2025 per TXMD's latest filing, up from $7.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $137.6 million in Q1 2021 to a low of $4.3 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $32.7 million, with a median of $11.9 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: tumbled 91.23% in 2023, then soared 47.91% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $64.9 million in 2021, then decreased by 24.02% to $49.3 million in 2022, then crashed by 91.23% to $4.3 million in 2023, then rose by 16.92% to $5.1 million in 2024, then skyrocketed by 47.91% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Cash & Equivalents are $7.5 million (Q4 2025), $7.1 million (Q3 2025), and $6.1 million (Q2 2025).